FDA has begun to reject ANDAs for generics tablets that are larger than their brand name counterpart, attorney Kurt Karst noted in a recent blog posting.
Karst, of Hyman, Phelps & McNamara, cited letters that FDA’s Office of Generic Drugs recently sent to companies with ANDAs...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?